Acrivon Therapeutics
ACRV
48 hedge funds and large institutions have $109M invested in Acrivon Therapeutics in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
14% more funds holding
Funds holding: 42 → 48 (+6)
11% more capital inflows, than outflows
Capital inflows: $3.4M | Capital outflows: $3.08M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.29% less ownership
Funds ownership: 68.99% → 68.7% (-0.29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$827K |
| 2 |
Renaissance Technologies
New York
|
+$476K |
| 3 |
Millennium Management
New York
|
+$443K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$249K |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$245K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NEA Management Company
Timonium,
Maryland
|
-$1.29M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.11M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$227K |
| 4 |
D.E. Shaw & Co
New York
|
-$157K |
| 5 |
JP Morgan Chase
New York
|
-$132K |
ACRV Hedge Fund Activity: Q1 2024 in Review
48 of the 6,966 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q1 2024, worth a combined $109M — up 46% from $74.5M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ACRV positions and 6 closed out — a net gain of 6 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $827K. The largest seller was NEA Management Company, exiting entirely with an estimated $1.29M sold.
- 48 institutional investors held Acrivon Therapeutics (ACRV) as of Q1 2024, up from 42 in Q4 2023.
- Funds reported $109M of Acrivon Therapeutics stock for Q1 2024, up 46% quarter-over-quarter.
- 12 funds opened new Acrivon Therapeutics positions in Q1 2024 and 6 closed out, a net change of +6 holders.
- The largest Acrivon Therapeutics buyer in Q1 2024 was BlackRock, an estimated $827K added.
- The largest Acrivon Therapeutics seller in Q1 2024 was NEA Management Company, an estimated $1.29M sold.
Based on aggregated 13F filings for Q1 2024.